



Abbott India Limited
Godrej BKC, Plot C-68, "G"Block,
15-16th Floor, Bandra-Kurla Complex,
Near MCA Club, Bandra (E),
Mumbai - 400 051. India

Registered Office:
3, Corporate Park,
Sion Trombay Road,
Mumbai - 400 071.India

Tel: (91-22) 5046 1000/2000
Fax : (91-22) 5016 9400
E-mail : webmasterindia@abbott.com
Website : www.abbott.co.in
CIN: L24239MH1944PLC007330

February 5, 2025

To,
BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

Scrip Code: 500488

Dear Sirs,

Sub: Outcome of Board Meeting

Ref: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Below is the outcome of the Board Meeting held today i.e., February 5, 2025:

Financial Results

Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors approved the Unaudited Financial Results of the Company for the quarter and nine months ended on December 31, 2024, along with the Limited Review Report issued by Walker Chandiook & Co LLP, Statutory Auditors of the Company. Copy of the same is enclosed herewith.

Re-appointment of Internal Auditors

Upon recommendation of the Audit Committee, the Board of Directors approved the re-appointment of M/s Deloitte Touche Tohmatsu India LLP, Chartered Accountants (LLP Identification Number AAE-8458) as the Internal Auditors of the Company for the financial year commencing from April 1, 2025 and ending on March 31, 2026.

Details pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 is enclosed as Annexure A.

Appointment of Mr. Harshraj Madan as Commercial Director – GI Businesses

Pursuant to Regulation 30 read with Clause 7 of Para A of Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that, upon recommendation of the Nomination and Remuneration Committee, the Board of Directors have approved the appointment and remuneration of Mr Harshraj Madan as Commercial Director – GI Business effective February 17, 2025. He will be part of the Senior Management team of the Company.

Details pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 and BSE Circular No. LIST/COMP/14/2018-19 dated June 20, 2018, is enclosed as Annexure B.



Abbott India Limited
Godrej BKC, Plot C-68, "G"Block,
15-16th Floor, Bandra-Kurla Complex,
Near MCA Club, Bandra (E),
Mumbai - 400 051. India

Registered Office:
3, Corporate Park,
Sion Trombay Road,
Mumbai - 400 071.India

Tel: (91-22) 5046 1000/2000
Fax : (91-22) 5016 9400
E-mail : webmasterindia@abbott.com
Website : www.abbott.co.in
CIN: L24239MH1944PLC007330

The Meeting of the Board of Directors of the Company commenced at 11.30 am and concluded at 1.15 pm.

This is for your information and record.

For **Abbott India Limited**

Sangeeta Shetty
Company Secretary
Membership No.: ACS 18865

Encl: a/a



Abbott India Limited
Godrej BKC, Plot C-68, "G" Block,
15-16th Floor, Bandra-Kurla Complex,
Near MCA Club, Bandra (E),
Mumbai - 400 051. India

Registered Office:
3, Corporate Park,
Sion Tronibay Road,
Mumbai - 400 071. India

Tel : (91-22) 5046 1000/2000
Fax : (91-22) 5016 9400
E-mail : webmasterindia@abbott.com
Website : www.abbott.co.in
CIN : L24239MH1944PLC007330

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2024

(Rs. in Crores except earnings per share)

	Particulars	Quarter ended			Nine months ended		Year ended
		December 31, 2024	September 30, 2024	December 31, 2023	December 31, 2024	December 31, 2023	March 31, 2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income						
	(a) Revenue from operations	1,614.28	1,632.67	1,437.14	4,804.56	4,410.28	5,848.91
	(b) Other income	71.75	60.48	55.61	199.56	167.12	248.27
	Total Income	1,686.03	1,693.15	1,492.75	5,004.12	4,577.40	6,097.18
2	Expenses						
	(a) Cost of materials consumed	116.10	172.06	116.63	434.44	403.88	565.67
	(b) Purchases of stock-in-trade	749.19	738.49	668.35	2,268.98	1,899.97	2,647.21
	(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	27.41	(8.79)	(8.19)	(62.60)	110.86	7.73
	(d) Employee benefits expense	134.68	147.40	139.19	443.14	431.34	576.58
	(e) Finance costs	2.26	2.50	3.17	7.51	9.64	12.45
	(f) Depreciation and amortisation expense	17.99	17.51	17.97	53.87	52.98	71.17
	(g) Other expenses	150.81	144.55	133.47	454.54	440.66	598.62
	Total Expenses	1,198.44	1,213.72	1,070.59	3,599.88	3,349.33	4,479.43
3	Profit before tax (1-2)	487.59	479.43	422.16	1,404.24	1,228.07	1,617.75
4	Tax expenses						
	(a) Current tax expense	121.49	121.03	109.43	355.24	319.60	415.43
	(b) Tax adjustment for earlier years	1.31	-	3.91	(0.04)	0.03	0.03
	(c) Deferred tax expense/(credit)	4.01	(0.21)	(2.16)	1.64	(5.72)	1.07
	Total Tax Expenses	126.81	120.82	111.18	356.84	313.91	416.53
5	Profit for the period / year (3-4)	360.78	358.61	310.98	1,047.40	914.16	1,201.22
6	Other Comprehensive Income						
	Items that will not be reclassified subsequently to Profit or Loss	0.01	0.01	1.21	0.02	3.63	0.03
	Income tax on above	-*	-*	(0.30)	-*	(0.91)	(0.01)
	Total Other Comprehensive Income, net of tax	0.01	0.01	0.91	0.02	2.72	0.02
7	Total Comprehensive Income for the period / year, net of tax (5+6)	360.79	358.62	311.89	1,047.42	916.88	1,201.24
8	Paid-up Equity Share Capital						
	(Face Value of Rs.10 per Equity Share)	21.25	21.25	21.25	21.25	21.25	21.25
9	Other Equity	-	-	-	-	-	3,677.64
10	Earnings per equity share - Basic/Diluted						
	(of Rs.10/- each) (not annualised for the Quarter & Nine months ended)	169.78	168.76	146.34	492.89	430.19	565.28

* Less than Rs. 50,000/-



NOTES :

- 1 The above financial results have been reviewed and recommended by the Audit Committee and thereafter approved by the Board of Directors at their meetings held on February 5, 2025.
- 2 The financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended and prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated July 5, 2016.
- 3 The financial results for quarter and nine months ended December 31, 2024 have been subjected to limited review by the statutory auditors of the Company. The Limited Review Report does not contain any modifications.
- 4 The Company has only one segment which is 'Pharmaceuticals'. Therefore, disclosure relating to segments is not applicable and accordingly not made.
- 5 Figures for the previous periods have been regrouped/reclassified wherever considered necessary.



Place : Mumbai
Date : February 5, 2025

For and on behalf of the Board of Directors of
Abbott India Limited

SWATI DALAL
Managing Director
DIN : 01513751

Walker Chandiook & Co LLP

16th Floor, Tower III,
One International Center,
S B Marg, Prabhadevi (W),
Mumbai - 400013
Maharashtra, India
T +91 22 6626 2600

Independent Auditor's Review Report on Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Abbott Inda Limited

1. We have reviewed the accompanying statement of unaudited financial results ('the Statement') of Abbott India Limited ('the Company') for the quarter ended 31 December 2024 and the year to date results for the period 01 April 2024 to 31 December 2024, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.


(This space has been left intentionally)



Abbott Inda Limited
Independent Auditor's Review Report on Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

5. The review of unaudited quarterly and year-to-date financial results for the period ended 31 December 2023 and audit of financial results for the year ended 31 March 2024 included in the Statement was carried out and reported by S R B C & CO LLP, Chartered Accountants, who has expressed unmodified conclusion vide their review report dated 01 February 2024 and unmodified opinion vide their audit report dated 09 May 2024, respectively, whose reports has been furnished to us and which have been relied upon by us for the purpose of our review of the Statement. Our conclusion is not modified in respect of this matter.

For Walker Chandiok & Co LLP
Chartered Accountants
Firm Registration No: 001076N/N500013



Ashish Gupta
Partner
Membership No. 504662

UDIN: 25504662BMOODM7812

Place: Mumbai
Date: 05 February 2025



Abbott India Limited
Godrej BKC, Plot C-68,"G"Block,
15-16th Floor, Bandra-Kurla Complex,
Near MCA Club, Bandra (E),
Mumbai - 400 051. India

Registered Office:
3, Corporate Park,
Sion Trombay Road,
Mumbai - 400 071.India

Tel: (91-22) 5046 1000/2000
Fax : (91-22) 5016 9400
E-mail : webmasterindia@abbott.com
Website : www.abbott.co.in
CIN: L24239MH1944PLC007330

Annexure A

Re-appointment of M/s Deloitte Touche Tohmatsu India LLP

Sr. No.	Particulars	Details
1.	Reason for change	Re-appointment
2.	Date of Appointment/ Cessation and Term	Re-appointment of M/s. Deloitte Touche Tohmatsu India LLP, Chartered Accountants (LLP Identification Number AAE-8458) as Internal Auditors of the Company for the financial year commencing from April 1, 2025 and ending on March 31, 2026.
3.	Disclosure of relationship with Directors	None
4.	Brief Profile	<p>Deloitte India has more than 36,000 professionals operating out of 14 cities - Ahmedabad, Bengaluru, Bhubaneswar, Chennai, Coimbatore, Goa, New Delhi, Hyderabad, Jamshedpur, Kochi, Kolkata, Mumbai, Noida and Pune.</p> <p>They are committed to becoming the undisputed leader in professional services in the areas of Assurance, Tax, Strategy, Risk & Transactions, Technology & Transformation. They serve public and private clients spanning multiple industries.</p> <p>Deloitte draw their strength from their people, which include 2506+ professionals in Assurance, 2835+ in Strategy, Risk & Transactions, 3216+ in Tax, 12,244+ in Technology & Transformation.</p> <p>Deloitte take pride in their ability to serve their clients distinctively by solving complex challenges, inspire their talent to deliver outstanding values and support their communities and society we live in. Their multi-disciplinary model ensures they serve their clients across businesses and deliver the right combination of local insight and international expertise.</p>



Abbott India Limited
Godrej BKC, Plot C-68,"G"Block,
15-16th Floor, Bandra-Kurla Complex,
Near MCA Club, Bandra (E),
Mumbai - 400 051. India

Registered Office:
3, Corporate Park,
Sion Trombay Road,
Mumbai - 400 071.India

Tel: (91-22) 5046 1000/2000
Fax : (91-22) 5016 9400
E-mail : webmasterindia@abbott.com
Website : www.abbott.co.in
CIN: L24239MH1944PLC007330

Annexure B

Appointment of Mr. Harshraj Madan as Commercial Director – GI Businesses

Sr. No.	Particulars	Details
1.	Reason for change	Appointment of Mr Harshraj Madan as Commercial Director – GI Business effective February 17, 2025. He will be part of the Senior Management team of the Company.
2.	Date of Appointment and Term	Effective February 17, 2025.
3.	Relationship inter-se Directors/Key Managerial Personnel/Senior Management	Mr Harshraj Madan is not related to any of the Directors/ Key Managerial Personnel/ Senior Management of the Company.
4.	Brief Profile	<p>Harshraj comes with over 16 years of diverse experience across Sales & Marketing, Entrepreneurship and Strategy. He has been working with Abbott in various capacities for over 7 years now, and his latest role was that of Commercial Director – Emerging Channel Business & Institution for Abbott EPD in India.</p> <p>Prior to his career at Abbott, Harshraj has worked across multiple countries, industries and organizations, including large MNCs. His experience in planning and execution ranges from operating at the grassroots level as the cofounder of a startup, to strategizing for Fortune 500 companies globally as a management consultant.</p> <p>Harshraj has proven success in setting up new Go-To-Market models in the channel business in the Indian Pharmaceutical Market and has also transformed established businesses to position them for higher growth.</p> <p>Harshraj holds an MBA from the Indian School of Business - Hyderabad and is an engineering graduate of Mumbai University.</p>